Cancer patients in SARS-CoV-2 infection: a single-center experience from Wuhan
- PMID: 33033507
- PMCID: PMC7532501
- DOI: 10.7150/jca.47065
Cancer patients in SARS-CoV-2 infection: a single-center experience from Wuhan
Abstract
Background: The Coronavirus disease 2019 (COVID-19) global pandemic has posed unprecedented challenges to the health-care systems all over the world. Among the booming literatures about COVID-19, there is yet a paucity of study addressing the association between COVID-19 and cancer, which is a rare comorbidity of COVID-19, as well as consensus for treatment of cancer in this pandemic. Methods: In this retrospective, single-center cohort study, information of all inpatient cases with laboratory-confirmed COVID-19 who had treatment outcome were collected from the designated departments in Zhongnan Hospital of Wuhan University, Wuhan, China on March 10, 2020. Demographic data, clinical information, and treatment outcomes were extracted from electronic medical records. Severe events were defined as admission to intensive care unit (ICU), the use of mechanical ventilation, or death. Result: A total of 716 patients with laboratory-confirmed COVID-19 infection were identified. Among them, a total of 12 cases (1.7%, 95% CI: 0.7%-2.6%) had history of cancer with 4 cases (33%) experienced severe events. Compared with cases without cancer, patients with cancer have higher risks of severe events (33% vs 7.7%, p=0.012) and deaths (25% vs 3.6%, p=0.009). Multivariable logistic regression model showed that cancer was independently associated with increased odds of severe events after adjusting for other risk factors (OR 6.51, 95% CI 1.72-24.64; p=0.006). Among COVID-19 patients with cancer, we found that patients older than 60 years (75%), with other comorbidities (50%), or experiencing anticancer treatment in past month (42.9%) had a numerically higher incidence of severe events. Conclusion: Cancer is a rare comorbidity of patients with COVID-19; however, it cannot be overemphasized due to its poorer outcomes. We propose that personalized treatment recommendation for cancer patients should be addressed during COVID-19 pandemic, along with meticulous personal protective protocols for them to mitigate the risk of SARS-CoV-2 infection.
Keywords: COVID-19; Cancer; Coronavirus; Pandemic; Therapy.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Similar articles
-
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016. doi: 10.1016/S2468-1253(20)30271-5. Epub 2020 Aug 28. Lancet Gastroenterol Hepatol. 2020. PMID: 32866433 Free PMC article.
-
Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study.Ann Intensive Care. 2020 Jul 31;10(1):99. doi: 10.1186/s13613-020-00706-3. Ann Intensive Care. 2020. PMID: 32737627 Free PMC article.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit.JAMA Netw Open. 2020 Jun 1;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270. JAMA Netw Open. 2020. PMID: 32543702 Free PMC article. Review.
-
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study.Thromb Res. 2021 Jun;202:17-23. doi: 10.1016/j.thromres.2021.03.006. Epub 2021 Mar 8. Thromb Res. 2021. PMID: 33711754 Free PMC article.
Cited by
-
Lymphocyte may be a reference index of the outcome of cancer patients with COVID-19.Aging (Albany NY). 2021 Mar 18;13(6):7733-7744. doi: 10.18632/aging.202741. Epub 2021 Mar 18. Aging (Albany NY). 2021. PMID: 33735106 Free PMC article.
-
The effects of the COVID-19 pandemic on psychological stress in breast cancer patients.BMC Cancer. 2021 Dec 31;21(1):1356. doi: 10.1186/s12885-021-09012-y. BMC Cancer. 2021. PMID: 34972520 Free PMC article.
-
Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis.JCO Glob Oncol. 2021 Aug;7:1286-1305. doi: 10.1200/GO.21.00072. JCO Glob Oncol. 2021. PMID: 34406802 Free PMC article.
-
Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C).J Clin Oncol. 2021 Jul 10;39(20):2232-2246. doi: 10.1200/JCO.21.01074. Epub 2021 Jun 4. J Clin Oncol. 2021. PMID: 34085538 Free PMC article.
-
Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.Rev Med Virol. 2022 Sep;32(5):e2352. doi: 10.1002/rmv.2352. Epub 2022 Apr 13. Rev Med Virol. 2022. PMID: 35416370 Free PMC article.
References
-
- Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020. [Online ahead of print] - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous